Yale University School of Medicine, Yale Cancer CenterNew Haven, Connecticut, United States
Disclosure information not submitted.
Paper 23 - A PHASE IA/IB, DOSE-ESCALATION/EXPANSION STUDY OF THE MDM2-P53 ANTAGONIST BRIGIMADLIN (BI 907828) IN PATIENTS WITH SOLID TUMORS: SAFETY AND EFFICACY IN PATIENTS WITH LIPOSARCOMA
Thursday, November 2, 20234:00 PM – 5:30 PM